Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > GPRC5D


Brief Information

Name:G-protein coupled receptor family C group 5member D
Target Synonym:G Protein-Coupled Receptor Class C Group 5 Member D,G-Protein Coupled Receptor Family C Group 5 Member D,G Protein-Coupled Receptor, Class C, Group 5, Member D,G Protein-Coupled Receptor, Family C, Group 5, Member D,GPRC5D,Orphan G-Protein Coupled Receptor
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CCHO-STP058-Cell-based assay

FACS Analysis of CHO/Human GPRC5D Stable Cell Line. FACS assay shows that Anti-GPRC5D antibody can bind to CHO/Human GPRC5D Stable Cell Line (Fig. B), and non-transfected CHO cells were used as a negative control (Fig. A). PE signal was used to evaluate the binding activity (QC tested).


Anti-GPRC5D Antibody, Human IgG4 captured on Protein A Chip can bind FITC-Labeled Human GPRC5D Protein, Flag,His Tag (Cat. No. GPD-HF2D7) with an affinity constant of 9.29 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).


Anti-GPRC5D Antibody immobilized on CM5 Chip can bind Cynomolgus GPRC5D, Flag,His Tag (Cat. No. GPD-C52D3) with an affinity constant of 0.122 μM as determined in a SPR assay (Biacore T200) (QC tested).

Synonym Name



G-protein coupled receptor family C group 5 member D (GPRC5D) is a retinoic acid-inducible 40 kDa protein with seven transmembrane segments and a short N terminal extracellular region. Widely expressed in the peripheral system. Expression pattern is high in pancreas, medium in kidney, small intestine, spleen and testis, low in lung, colon, leukocyte, prostate and thymus and not detectable in brain, heart, liver, placenta, skeletal muscle and ovary.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
OriC-321 OriC-321; Ori-C-321 Phase 1 Clinical Zhejiang University Multiple Myeloma Details
MCARH-109 Phase 1 Clinical Memorial Sloan Kettering Cancer Center Multiple Myeloma Details
RO-7425781 RO-7425781 Phase 1 Clinical F. Hoffmann-La Roche Ltd Multiple Myeloma Details
CAR-GPRC5D CAR-GPRC5D Phase 1 Clinical Nanjing Iaso Biotherapeutics Co Ltd Leukemia, Plasma Cell; Multiple Myeloma Details
Autologous anti-BCMA/GPRC5D CAR-T cell therapy (Xuzhou Medical University) Phase 2 Clinical Xuzhou Medical University (Xzmu) Multiple Myeloma Details
Ori-CAR-017 OriCAR-017; Ori-CAR-017 Phase 1 Clinical OriCell Therapeutics Co Ltd Multiple Myeloma Details
Talquetamab JNJ-7564; JNJ-64407564 Phase 3 Clinical Janssen Global Services Llc, Genmab A/S Hematologic Neoplasms; Multiple Myeloma Details
LM-305 LM-305 Phase 1 Clinical LaNova Medicines Ltd Multiple Myeloma Details
RG-6234 RG-6234 Phase 1 Clinical F. Hoffmann-La Roche Ltd Multiple Myeloma Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message